Profile data is unavailable for this security.
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
- Revenue in USD (TTM)6.48m
- Net income in USD-190.05m
- Incorporated2007
- Employees181.00
- LocationFate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
- Phone+1 (858) 875-1803
- Fax+1 (302) 636-5454
- Websitehttps://fatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
enGene Holdings Inc | 0.00 | -106.80m | 387.65m | 33.00 | -- | 3.27 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 388.71m | 66.00 | -- | 1.64 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Lenz Therapeutics Inc | 0.00 | -117.37m | 390.42m | 6.00 | -- | 1.97 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Jasper Therapeutics Inc | 0.00 | -63.93m | 391.62m | 45.00 | -- | 3.46 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Contineum Therapeutics Inc | 50.00m | 19.13m | 394.08m | 31.00 | 20.13 | -- | 20.36 | 7.88 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Fibrobiologics Inc | 0.00 | -22.53m | 398.52m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -240.16m | 407.99m | 130.00 | -- | 0.6324 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
Esperion Therapeutics Inc | 229.74m | -86.51m | 409.23m | 240.00 | -- | -- | -- | 1.78 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Fate Therapeutics Inc | 6.48m | -190.05m | 418.90m | 181.00 | -- | 0.9828 | -- | 64.67 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Theravance Biopharma Inc | 61.51m | -44.77m | 419.22m | 99.00 | -- | 2.04 | -- | 6.82 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Editas Medicine Inc | 69.41m | -166.13m | 427.64m | 265.00 | -- | 1.45 | -- | 6.16 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 435.78m | 255.00 | -- | 0.7461 | -- | 27.15 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
Ocugen Inc | 7.05m | -58.50m | 445.18m | 65.00 | -- | 14.71 | -- | 63.15 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Annexon Inc | 0.00 | -120.74m | 446.35m | 70.00 | -- | 1.67 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Tscan Therapeutics Inc | 14.81m | -96.80m | 451.98m | 161.00 | -- | 3.33 | -- | 30.51 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Voyager Therapeutics Inc | 119.04m | -3.04m | 456.91m | 162.00 | -- | 1.34 | 300.99 | 3.84 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 31 Mar 2024 | 13.17m | 11.57% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 9.84m | 8.65% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.04m | 7.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.88m | 6.04% |
Deep Track Capital LPas of 31 Mar 2024 | 5.57m | 4.90% |
Bellevue Asset Management AGas of 31 Mar 2024 | 4.84m | 4.25% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.13m | 2.75% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.82m | 2.48% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 2.73m | 2.40% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 2.56m | 2.25% |